Companies in the Global Vaccine Delivery Devices Market Expedite Product Innovations to Stay at Forefront in the Market in the COVID-19 Pandemic

April 20, 2021

The growing prevalence of medical diseases and infections is projected to rev up the demand for vaccine devices in the healthcare sector. Manufacturers are increasingly witnessing demand for vaccine delivery devices due to the increase in a number of diabetic patients globally.

Fact.MR has recently compiled a report, which reveals that the vaccine delivery devices market globally is projected to reflect an impressive CAGR over the forecast period, 2017 – 2022.

For more insights, Request a Sample of Vaccine Delivery Devices Market Report  https://www.factmr.com/connectus/sample?flag=S&rep_id=178

Factors Propelling Global Market Growth

The growing need for vaccination for the treatment of various medical diseases and infections has led to an upsurge in demand for vaccine delivery devices globally. In a report published by the CDC, order to protect from diseases and infections such as meningitis, hepatitis A, and hepatitis B, and influenza immunization should be done during the birth, adolescence, and adulthood period.

The increasing prevalence of type 1 diabetes and type 2 diabetes among the adult and geriatric population has led to a surge in demand for vaccine delivery devices in the healthcare sector. Type 2 diabetic patients are prescribed insulin doses such as Lantus and Novorapid by healthcare professionals. The increasing use of insulin among diabetic patients has led to a surge in demand for vaccine devices globally. These factors are expected to contribute towards the global market growth of vaccine delivery devices significantly during the projected period.

Moreover, healthcare manufacturers are increasingly integrating enhanced technology to offer painless vaccine delivery devices. Recently published news update, a new device known as ‘Microneedle Patches’ is developed, which has needle-free attributes and injects a dose of vaccine within a fraction of seconds. These factors are projected to impact the global market growth of vaccine delivery devices positively throughout 2022.

Syringes to Represent a Leading Segment

Intramuscular vaccine among other routes of administration is projected to represent a relatively high growth in terms of revenue in the global market of vaccine delivery devices. This segment will represent more than US$ 1,000 Mn by 2022 – end. The intramuscular vaccine is projected to reflect a relatively high CAGR as compared to other routes of administration in the global market of vaccine delivery devices during the predicted period. In terms of revenue, subcutaneous is projected to represent a significant growth after the intramuscular segment throughout 2022. This segment will reflect a significant CAGR after the intramuscular segment in the global market during the projected period.

Syringes among other products are projected to reflect a relatively high CAGR in the global market of vaccine delivery devices throughout 2022. In terms of revenue, this segment will represent a relatively high growth in the market globally. This segment will represent more than US$ 900 Mn in 2017. North America among other regions is projected to represent the major market for vaccine delivery devices in the global market. Jet devices are projected to represent a significant growth after syringes in the global market of vaccine delivery devices by the end of 2022.

For comprehensive insights on this market adoption, ask an analyst here  https://www.factmr.com/connectus/sample?flag=AE&rep_id=178

Market Players

Leading players in the global market of vaccine delivery devices are PharmaJet, Inc, Becton Dickinson & Company, Vaxxas Pty. Ltd, Valeritas Holdings, Inc, Schott AG, Gerresheimer AG, 3M Company, and Antares Pharma, Inc.

Explore Fact.MR’s Coverage on the Healthcare Domain

Vaccine Management Solution Market: A recent study by Fact.MR on the Vaccine Management Solution Market offers a 10-year forecast analysis for the period 2020 to 2030. The study analyzes key trends that are currently influencing the growth of the market. This report covers key dynamics, including drivers, restraints, and opportunities for leading market players along with key stakeholders and emerging players.

Respiratory Virus Vaccines Market: Fact.MR’s extensive coverage on the Respiratory Virus Vaccines Market offers in-depth insights about the prominent growth dynamics that are likely to aid the expansion of growth prospects in the near future. Data has been presented in the form of key segments across prominent geographies, along with important information concerning key manufacturers operating within the industry.

Leprosy Vaccines Market: The Leprosy Vaccines Market study published by Fact.MR offers an unbiased analysis of the prominent drivers, opportunities and trends expected to shape future expansion outlook. The report provides a comprehensive assessment on the prominent segments and geographies which are likely to benefit market players in the forthcoming years.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in the US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed.

Research Insight: https://www.factmr.com/report/178/vaccine-delivery-devices-market

Content Source: https://www.factmr.com/media-release/168/vaccine-delivery-devices-market

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel:+1 (628) 251-1583
E: 
sales@factmr.com
Follow Us:
LinkedIn | Twitter

SourceFact.MR

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”